EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Medical cannabis improved self-reported spasticity rating in patients with chronic spinal cord injury: a placebo-controlled, double-blind, crossover pilot clinical trial

Nattha Boonthanakorn iD, Sintip Pattanakuhar iD, Pratchayapon Kammuang-Lue, Siam Tongprasert iD, Apichana Kovindha

Therapeutic Advances in Neurological Disorders · 2026-08 · 19

DOI: 10.1177/17562864261468464 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Neurological Disorders, online erschienen am 01.08.2026. Verfasst von Nattha Boonthanakorn und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Government Pharmaceutical Organization (GPO) of Thailand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Previous studies demonstrated that cannabinoids may reduce spasticity in patients with spinal cord injury (SCI); however, the effect of naturally extracted THC:CBD oil, the most commonly used naturally extracted cannabinoids, has yet to be elucidated.

Objectives

To assess the effect of a 1:1 THC:CBD oil on reducing spasticity in chronic SCI patients Design: A single-center, placebo-controlled, double-blind crossover clinical trial.

Methods

Sixteen chronic SCI patients with intractable spasticity were randomly assigned to either the intervention (1:1 THC:CBD oil) or control (placebo) phase for 1 month, then crossed over. The primary outcome (combined Ashworth Scale [AS] of all involved muscle groups) and the secondary outcomes, including patient-rated visual analog scale (VAS) of spasticity, were assessed before and after both phases and analyzed using a multilevel mixed-effects model.

Results

All participants completed the study. The average (SD) dose of THC:CBD oil was 11.6 (1.3) mg. No significant difference in the total AS score for all involved muscle groups was found between the pre- and post-treatment phases, or between the experimental and control phases (all p > 0.05). A significant reduction was observed in the patient rating VAS (effect size = −13.9 [95% CI: −25.5 to −2.3; p = 0.010).

Conclusion

In people with chronic SCI who had intractable spasticity, there was no statistically significant effect of 1:1 THC:CBD oil on spasticity-related outcomes, except for patient rating VAS reduction. Further studies are needed to evaluate the efficacy of higher doses of THC (>12 mg/day) and to use patient-reported spasticity scores as the primary outcome measure.

Trial registration

The study was registered with the Thai Clinical Trials Registry (TCTR identification number: TCTR20220329001).

Schlagwörter

Stichwörter der Autor:innen

cannabidiolcannabinoidsspasticityspinal cord injurytetrahydrocannabinol

Autor:innen und Institutionen

  • Department of Rehabilitation Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Department of Rehabilitation Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Biomedical Engineering, Faculty of Engineering, University of Strathclyde, Woftson Building, 106 Rottenrow East, Glasgow G4 0NW, UK.

ORCID-Profile: Nattha Boonthanakorn, Sintip Pattanakuhar, Siam Tongprasert

Förderung

  • Government Pharmaceutical Organization (GPO) of Thailand

Zitieren

APA

Boonthanakorn, N., Pattanakuhar, S., Kammuang-Lue, P., Tongprasert, S., & Kovindha, A. (2026). Medical cannabis improved self-reported spasticity rating in patients with chronic spinal cord injury: a placebo-controlled, double-blind, crossover pilot clinical trial. Therapeutic Advances in Neurological Disorders, 19. https://doi.org/10.1177/17562864261468464

Vancouver

Boonthanakorn N, Pattanakuhar S, Kammuang-Lue P, Tongprasert S, Kovindha A. Medical cannabis improved self-reported spasticity rating in patients with chronic spinal cord injury: a placebo-controlled, double-blind, crossover pilot clinical trial. Therapeutic Advances in Neurological Disorders. 2026;19. doi:10.1177/17562864261468464

BibTeX
@article{Boonthanakorn2026,
  author = {Boonthanakorn, Nattha and Pattanakuhar, Sintip and Kammuang-Lue, Pratchayapon and Tongprasert, Siam and Kovindha, Apichana},
  title = {Medical cannabis improved self-reported spasticity rating in patients with chronic spinal cord injury: a placebo-controlled, double-blind, crossover pilot clinical trial},
  journal = {Therapeutic Advances in Neurological Disorders},
  year = {2026},
  volume = {19},
  doi = {10.1177/17562864261468464}
}
Kostenlos starten →